IOPROMIDE
Neuroendocrine Carcinoma of Pancreas
Seoul National University HospitalSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Neuroendocrine Carcinoma of Pancreas cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Temsirolimus University of Southern California | Phase 2 | B |
Everolimus Emory University | Phase 2 | B |
Carboplatin ECOG-ACRIN Cancer Research Group | Phase 2 | B |
Oxodotreotide Alliance for Clinical Trials in Oncology | Phase 2 | B |
Irinotecan Roswell Park Cancer Institute | Phase 2 | B |
View all 27 →
Same molecule, other indications
IOPROMIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →